Coronado is a biopharmaceutical company focused on novel immunotherapy biologic agents for autoimmune diseases and cancer. Coronado's two principal pharmaceutical product candidates are initially targeted for clinical development for inflammatory bowel disease, multiple sclerosis and acute myeloid leukemia.

NEWS

May 8, 2013:

CNDO Coronado Biosciences Reports Financial Results for the First Quarter Ended March 31, 2013

May 7, 2013:

CNDO Coronado Biosciences Appoints Thomas F. Schaible, Ph.D. As Project Leader, Inflammatory Bowel Disease

May 6, 2013:

CNDO Coronado Biosciences to Present at the Bank of America Merrill Lynch 2013 Health Care Conference

May 1, 2013:

CNDO Coronado Biosciences to Report First Quarter 2013 Financial Results

CORONADO IN THE NEWS

April 23, 2013:

The Hygiene Hypothesis: Too Clean for Our Own Good?
By: Chris Leach at Insulin Nation

April 8, 2013:

Interview with Dr. Harlan F. Weisman, Coronado’s Chairman and CEO, with Pat Farnack of WCBS Newsradio 880 on the Health & Well Being Report.
Published on CBS New York

All News

DEVELOPMENT PIPELINE

TSO

TSO (Trichuris suis ova or CNDO-201) is a biologic for the treatment of autoimmune diseases, such as Crohn's disease, ulcerative colitis and multiple sclerosis.

CNDO-109

CNDO-109 is a biologic that activates natural killer (NK) cells for the treatment of acute myeloid leukemia (AML) and solid tumors.

 

ONGOING CLINICAL TRIALS

Click here for more clinical trial information.

 

INVESTOR AREA

Click here for more investor information.

UPCOMING EVENTS

 

View All Events & Webcasts

LITERATURE

Publications

TSO Publications
CNDO-109 Publications